Open-Label, Multicenter, Phase I Dose Escalation Study of MEN1309, a CD205 Antibody-Drug Conjugate,in Patients With CD205-Positive Metastatic Solid Tumors and Non-Hodgkin Lymphoma

Trial Profile

Open-Label, Multicenter, Phase I Dose Escalation Study of MEN1309, a CD205 Antibody-Drug Conjugate,in Patients With CD205-Positive Metastatic Solid Tumors and Non-Hodgkin Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2018

At a glance

  • Drugs MEN 1309 (Primary)
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms CD205-SHUTTLE
  • Sponsors Menarini
  • Most Recent Events

    • 12 Sep 2017 Status changed from planning to recruiting according to a Oxford BioTherapeutics media release.
    • 31 Jan 2017 New trial record
    • 26 Jan 2017 According to a Oxford BioTherapeutics media release, the company plans to initiate this study in mid-2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top